QDEL Earnings Date: Nov 3, 2026 (Estimated) — QuidelOrtho Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is QDEL's next earnings date?
QuidelOrtho Corporation (QDEL) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.20 on revenue of $627.8M.
How did QDEL do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), QuidelOrtho Corporation posted EPS of $0.13 versus the -$0.05 estimate, a beat of 1400.0%. Revenue was $631.0M against a $618.7M estimate. The stock's 1-day post-earnings move was -24.7%.
How much does QDEL stock move after earnings?
QDEL beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.9% (up or down) in the day after earnings.
About QuidelOrtho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.05 | 0.13 | +1400.00% | $631.0M | ✅ Beat | -24.72% | -7.54% | -14.40% |
| 2026-05-05 | Q1 2026 | 0.41 | -0.04 | -109.76% | $619.8M | ❌ Miss | -6.00% | -4.63% | +31.22% |
| 2026-02-11 | Q4 2025 | 0.43 | 0.46 | +6.98% | $723.6M | ✅ Beat | -17.59% | -18.02% | -40.63% |
| 2025-11-05 | Q3 2025 | 0.48 | 0.80 | +66.67% | $699.9M | ✅ Beat | -22.32% | -17.46% | +1.42% |
| 2025-08-05 | Q2 2025 | 0.01 | 0.12 | +1100.00% | $613.9M | ✅ Beat | -1.01% | +6.38% | +17.36% |
| 2025-02-12 | Q4 2024 | 0.58 | 0.63 | +8.62% | $707.8M | ✅ Beat | +4.28% | +2.73% | -9.56% |
| 2024-11-07 | Q3 2024 | 0.32 | 0.85 | +165.62% | $727.1M | ✅ Beat | +12.61% | +0.28% | +4.32% |
| 2024-07-31 | Q2 2024 | -0.23 | -0.07 | +69.57% | $637.0M | ✅ Beat | +6.90% | +0.76% | +10.92% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $556.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 58.8% | $327.4M | +5.4% | $399.6M | $406.7M | $310.7M | $381.4M |
| EMEA | 16.4% | $91.2M | +4.5% | $85.9M | $88.9M | $87.3M | $91.8M |
| Latin America | 12.6% | $70.2M | — | — | — | — | — |
| China | 12.2% | $67.8M | -18.7% | — | $75.0M | $83.4M | $84.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.